CCIA
PGNX

Campbell & Co Investment Adviser’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21,410
Closed -$172K – 578
2018
Q2 		$172K Buy
21,410
+5,708
+36% +$43.6K 0.13% 324
2018
Q1 		$117K Buy
+15,702
New +$104K 0.1% 331

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Campbell & Co Investment Adviser's PGNX Position: Q3 2018 in Review

Campbell & Co Investment Adviser sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 21,410 shares — an estimated $172K sold.

Campbell & Co Investment Adviser first reported a position in PGNX in Q1 2018 and held it in 2 quarters. The position peaked at $172K in Q2 2018. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Campbell & Co Investment Adviser reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 21,410 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $172K.
  • Campbell & Co Investment Adviser first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Progenics Pharmaceuticals Inc position peaked at $172K in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2018, filed 8 Nov 2018.